More on Mela Sciences (MELA): Q4 comes in line with estimates. Net loss for quarter was $6.1M, or $0.19 per diluted share, compared to a net loss of $4.5M, or $0.17 per diluted share for Q411. The higher net losses can be attributed to greater SG&A costs, and an increase in direct costs associated with the placement of MelaFind systems in dermatologists' offices. Total revenues were boosted by increased installation of its MelaFind, with 20 additional user agreements signed in Q4. Shares +4.2% AH.